Trial Profile
A Multicenter Phase II Pilot Open Label Study to Evaluate the Efficacy and Safety of BKM120 in the Treatment of Patients With Advanced or Metastatic Differentiated Thyroid Cancers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2018
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary)
- Indications Carcinoma; Follicular lymphoma; Thyroid cancer
- Focus Therapeutic Use
- 06 Jul 2017 This trial has been completed in France, according to European Clinical Trials Database
- 25 Apr 2013 New trial record